Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing

Core Points - Procaps Group, S.A. has received formal notice from Nasdaq regarding its failure to timely file the Form 20-F for the fiscal year ended December 31, 2023, which may lead to suspension and delisting of its securities unless a hearing is requested [1] - The Company plans to request a hearing before the Nasdaq Hearings Panel and seek a stay of any suspension action [2] - Procaps is actively working to complete an independent investigation and file the Form 20-F with the SEC as soon as possible [3] Company Overview - Procaps Group, S.A. is a leading developer of pharmaceutical and nutraceutical solutions, with a presence in over 50 countries and nearly 5,000 employees [4]